Trial Profile
Dinutuximab + interleukin-2 + isotretinoin in patients with high-risk neuroblastoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2015
Price :
$35
*
At a glance
- Drugs Dinutuximab (Primary) ; Interleukin-2; Isotretinoin
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use